Inflammation; Skin
Conditions
Brief summary
A noticeably increasing number of patients are asking for naturally based extracts and ingredients as supplementary dermatologic remedies. Patients are seeking natural and cost-effective skin care alternatives in place of prescription medications and procedures. Our study will evaluate the effects of oral curcumin and turmeric on sebum production in healthy subjects.
Detailed description
Turmeric extracts and curcumin have been shown to be safe, even at high doses without significant side-effects. Previous clinical studies in other inflammatory skin diseases have shown that a dosage of curcumin at 6,000 mg daily was effective while lower doses were not. In a human phase I clinical trial examining the effects of high dose curcumin in preventing premalignant lesions, even curcumin doses as high as 8,000 mg/day resulted in no toxic effects after 3 months. This study will involve participant ingestion of 6,000 mg/day of turmeric or curcumin to assess how this affects their sebum production. The investigators will also be collecting stool from the study subjects, and examining how the curcumin and turmeric may modulate their gut microbiome. The investigators will specifically be looking to see if curcumin or turmeric have any changes on the gut flora towards bacteria that produce more short chain fatty acids. Certain bacteria that make up the microbiome produce short chain fatty acids, such as butyrate and propionate, which have demonstrated anti-inflammatory properties. Thus, it would be interesting to see if turmeric or curcumin exert any of its anti-inflammatory effects via modulation of the microbiome.
Interventions
DIETARY_SUPPLEMENTTurmeric tablets
DIETARY_SUPPLEMENTCurcumin and Bioperine tablets
DIETARY_SUPPLEMENTPlacebo tablets
Sponsors
University of California, Davis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 18 to 50 years of age, and 2. Subject must be able to read and comprehend study procedures and consent forms.
Exclusion criteria
1. Subject should be generally healthy and have no smoking history in the past one year, and must have no history of diabetes, metabolic syndrome, known cardiovascular disease, malignancy, kidney disease, or chronic steroid use. 2. Those who used topical medications in the past two weeks or systemic antibiotics or oral probiotics within one month of starting the study. 3. Subjects who are postmenopausal 4. Those who are pregnant or breastfeeding. 5. Those that are prisoners or cognitively impaired. 6. Those who have a known allergy to black pepper should not participate in this clinical trial, since one of the treatments consists of tablets containing a small amount (1.25mg/tablet) of black pepper. 7. Those that are taking angiotensin converting enzyme inhibitor medications or angiotensin receptor blocker medications for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sebum production | 8 weeks | Sebutapes will be used to measure sebum production at each visit. The sebutapes will then be collected and analyzed for fatty acids and lipid production. |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in Sebum profile, such as inflammatory markers at 8 weeks | 8 weeks |
| Change in stool microbiome diversity (optional collections for subjects) from baseline at 8 weeks | 8 weeks |
Countries
United States
Outcome results
None listed